Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2016
At a glance
- Drugs Clobetasol (Primary)
- Indications Bullous pemphigoid
- Focus Therapeutic Use
- Acronyms RECOPB
- 30 Apr 2015 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 30 Apr 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov.
- 30 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.